X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare with AJANTA PHARMA - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ALKEM LABORATORIES vs AJANTA PHARMA - Comparison Results

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ALKEM LABORATORIES AJANTA PHARMA ALKEM LABORATORIES/
AJANTA PHARMA
 
P/E (TTM) x - 24.9 - View Chart
P/BV x 7.4 10.3 72.2% View Chart
Dividend Yield % 0.6 0.6 100.1%  

Financials

 ALKEM LABORATORIES   AJANTA PHARMA
EQUITY SHARE DATA
    ALKEM LABORATORIES
Mar-16
AJANTA PHARMA
Mar-16
ALKEM LABORATORIES/
AJANTA PHARMA
5-Yr Chart
Click to enlarge
High Rs1,5891,720 92.4%   
Low Rs1,2321,103 111.7%   
Sales per share (Unadj.) Rs417.5194.6 214.5%  
Earnings per share (Unadj.) Rs56.345.2 124.5%  
Cash flow per share (Unadj.) Rs64.750.3 128.7%  
Dividends per share (Unadj.) Rs12.708.00 158.8%  
Dividend yield (eoy) %0.90.6 158.9%  
Book value per share (Unadj.) Rs292.9132.0 221.9%  
Shares outstanding (eoy) m119.5788.77 134.7%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x3.47.3 46.6%   
Avg P/E ratio x25.131.2 80.3%  
P/CF ratio (eoy) x21.828.1 77.7%  
Price / Book Value ratio x4.810.7 45.0%  
Dividend payout %22.617.7 127.5%   
Avg Mkt Cap Rs m168,653125,299 134.6%   
No. of employees `000NANA-   
Total wages/salary Rs m9,1712,570 356.9%   
Avg. sales/employee Rs ThNMNM-  
Avg. wages/employee Rs ThNMNM-  
Avg. net profit/employee Rs ThNMNM-  
INCOME DATA
Net Sales Rs m49,91517,275 288.9%  
Other income Rs m1,645166 989.2%   
Total revenues Rs m51,56117,442 295.6%   
Gross profit Rs m8,4825,807 146.1%  
Depreciation Rs m1,006451 223.2%   
Interest Rs m67149 1,371.4%   
Profit before tax Rs m8,4515,474 154.4%   
Minority Interest Rs m-1140-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,6061,460 110.0%   
Profit after tax Rs m6,7314,014 167.7%  
Gross profit margin %17.033.6 50.6%  
Effective tax rate %19.026.7 71.3%   
Net profit margin %13.523.2 58.0%  
BALANCE SHEET DATA
Current assets Rs m27,0627,639 354.3%   
Current liabilities Rs m15,3242,715 564.5%   
Net working cap to sales %23.528.5 82.5%  
Current ratio x1.82.8 62.8%  
Inventory Days Days6743 153.8%  
Debtors Days Days4179 52.5%  
Net fixed assets Rs m12,6106,914 182.4%   
Share capital Rs m239177 135.2%   
"Free" reserves Rs m34,49011,442 301.4%   
Net worth Rs m35,02711,721 298.8%   
Long term debt Rs m1,212149 814.8%   
Total assets Rs m54,38714,814 367.1%  
Interest coverage x13.6112.9 12.0%   
Debt to equity ratio x00 272.6%  
Sales to assets ratio x0.91.2 78.7%   
Return on assets %13.627.4 49.6%  
Return on equity %19.234.2 56.1%  
Return on capital %24.946.5 53.4%  
Exports to sales %12.955.1 23.5%   
Imports to sales %3.16.0 51.4%   
Exports (fob) Rs m6,4619,527 67.8%   
Imports (cif) Rs m1,5401,038 148.4%   
Fx inflow Rs m6,56310,422 63.0%   
Fx outflow Rs m3,0121,678 179.5%   
Net fx Rs m3,5528,744 40.6%   
CASH FLOW
From Operations Rs m7,2593,264 222.4%  
From Investments Rs m1,864-2,093 -89.1%  
From Financial Activity Rs m-9,273-1,186 782.0%  
Net Cashflow Rs m-150-15 1,013.5%  

Share Holding

Indian Promoters % 66.9 73.8 90.7%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 33.1 1.6 2,135.5%  
FIIs % 0.0 7.6 -  
ADR/GDR % 0.0 0.0 -  
Free float % 0.0 17.0 -  
Shareholders   68,381 20,968 326.1%  
Pledged promoter(s) holding % 0.0 4.4 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ALKEM LABORATORIES With:   PIRAMAL ENTERPRISES  GSK PHARMA  PLETHICO PHARMA  DR. REDDYS LAB  NOVARTIS  

Compare ALKEM LABORATORIES With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Global Stock Markets Chart Modest Gains(RoundUp)

Global financial markets ended the holiday shortened week with modest gains. The rally put behind days of decline as concerns regarding swift interest rates hikes were put to ease.

Related Views on News

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

The Foundation for Sensex 100,000 is Laid(The 5 Minute Wrapup)

Feb 17, 2018

Top three reasons for Tanushree's presentation at Equitymaster Conference to be centered around a possible 30% correction.

India's Rs 1,66,276 Crore Problem(Vivek Kaul's Diary)

Feb 15, 2018

That's the loss, the government owned public sector enterprises are expected to make this year.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

How I Beat the Index by 2x... And Why I Believe This Could Happen Again(Smart Contrarian)

Feb 12, 2018

Will Microcap Millionaires be able to replicate its past performance of beating the index by 2x?

NPAs Set to Rise Further with New RBI Rules(Chart Of The Day)

Feb 15, 2018

The RBI overhauls bad loan framework. Banks may come under additional pressure due to rising NPAs and increased provisioning.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

ALKEM LABORATORIES SHARE PRICE


Feb 23, 2018 (Close)

TRACK ALKEM LABORATORIES

  • Track your investment in ALKEM LABORATORIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ALKEM LABORATORIES

ALKEM LABORATORIES 8-QTR ANALYSIS

COMPARE ALKEM LABORATORIES WITH

MARKET STATS